August 8, 2025 — BiotechReporter.news – Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) reported its second-quarter financial results and recent highlights, focusing on the development of pelareorep. According to CEO Jared Kelly, the company is shifting from proof-of-concept studies towards regulatory clarity, aiming to solidify its position in gastrointestinal tumor immunotherapy.
Key highlights include translational data presented at the American Society of Clinical Oncology Annual Meeting, which further demonstrates pelareorep’s mechanism of action. The company also hired Jared Kelly as CEO and Andrew Aromando as Chief Business Officer. Clinical data analysis indicates pelareorep’s potential to improve survival rates in metastatic pancreatic ductal adenocarcinoma and breast cancer. A key opinion leader webinar underscored pelareorep’s opportunity in gastrointestinal cancers, leading to a strategic decision to pursue a registration-enabling pivotal study in first-line mPDAC. The company is also committed to limiting dilutive financing.
As of June 30, 2025, Oncolytics reported $14.6 million in cash and cash equivalents, projecting a cash runway into the first quarter of 2026. The net loss for the second quarter of 2025 was $6.2 million, compared to $7.3 million for the second quarter of 2024.
Anticipated milestones include providing an updated clinical timeline for the registration-enabling pivotal study in Q3 2025 and initiating start-up activities for the study as early as Q4 2025.
Management is hosting the Annual General Meeting later today at 10:00 a.m. ET.
Contact:
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com
Source: Oncolytics Biotech® Inc.
